CEO Converts $10.5M in Preferred Stock to Common Shares
Summary
Sensei Biotherapeutics' CEO, Parikh Anand Kiran, converted over $10.5 million worth of Series B Preferred Stock into common shares, significantly increasing his direct common stock ownership as a result of a prior merger agreement.
Key Events · Ownership and Investor Activity · SNSE
-
CEO Converts Preferred Stock
CEO Parikh Anand Kiran converted 761.428 shares of Series B Preferred Stock into 761,428 shares of common stock on June 15, 2026.
-
Significant Ownership Shift
The conversion represents a $10,545,778 transaction, significantly increasing the CEO's direct common stock holdings, representing over 56% of the company's market capitalization.
-
Post-Merger Transaction
This conversion is a mechanical step related to the February 2026 merger agreement and subsequent recapitalization, solidifying the CEO's direct common stock ownership.
Analysis · SNSE · Life Sciences
This Form 4 reports a substantial conversion of Series B Preferred Stock into common stock by CEO Parikh Anand Kiran, valued at over $10.5 million. While a conversion (Code C) is a mechanical transaction rather than a discretionary open-market purchase, it significantly increases the CEO's direct exposure to the common stock's performance. This transaction is a direct outcome of the company's recent transformative acquisition and private placement, aligning the CEO's incentives more closely with common shareholders.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNSE was trading at $13.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.6M. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.